Differential qualitative responses to rivastigmine in APOE ɛ4 carriers and noncarriers


ABSTRACTThis retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6–12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) ɛ4 allele. APOE data were collected from patients who consented to pharmacogenetic testing… (More)
DOI: 10.1038/sj.tpj.6500267


3 Figures and Tables